R. Funke

发表

EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation

M. Gerritsen, D. J. Matthews, V. Vysotskaia, 2008, Clinical Cancer Research.

Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1–selected patients with non-small cell lung cancer (NSCLC).

S. Gettinger, C. Chappey, N. Rizvi, 2015 .

Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC).

T. Powles, J. Sosman, M. Sznol, 2013 .

Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.

G. Giaccone, F. Hodi, S. Gettinger, 2017 .

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open‐Label Study of Atezolizumab in PD‐L1–Selected Patients With NSCLC

S. Gettinger, N. Rizvi, J. Chaft, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract 2651: Clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma

P. Hegde, H. Hurwitz, J. Bendell, 2016 .

XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding to Treatment with Either Gefitinib or Erlotinib

H. Wakelee, T. Lynch, V. Miller, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I study of XL647, an EGFR, HER2, VEGFR2 inhibitor, administered orally daily to patients (pts) with advanced solid malignancies (ASM)

H. Wakelee, B. Sikic, J. Molina, 2008 .

Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC).

Suzanne F. Jones, M. Sznol, J. Bendell, 2015 .

Non-viral precision T cell receptor replacement for personalized cell therapy

Katie M. Campbell, D. Baltimore, J. Sosman, 2022, Nature.

Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer

E. Winer, A. Schneeweiss, S. Loi, 2018, The New England journal of medicine.

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Suzanne F. Jones, Fabien Gaire, P. Hegde, 2016, Nature Communications.

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

G. Hampton, P. Hegde, I. Wistuba, 2018, Proceedings of the National Academy of Sciences.

Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial

S. Adams, L. Molinero, J. Diamond, 2019, JAMA oncology.

OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients

G. Hampton, P. Hegde, G. Frampton, 2017 .

Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

S. Adams, L. Molinero, J. Diamond, 2016 .

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

G. Giaccone, F. Hodi, S. Gettinger, 2018, European journal of cancer.

Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab +nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer

E. Winer, A. Schneeweiss, S. Loi, 2019, General Session Abstracts.

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).

H. Hurwitz, J. Bendell, M. Pishvaian, 2015 .

Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

David S. Shames, Matthew D. Hellmann, Garrett M. Frampton, 2016 .

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

G. Giaccone, F. Hodi, S. Gettinger, 2015 .

Abstract P2-11-06: Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer

S. Adams, L. Molinero, J. Diamond, 2016 .

A phase Ia/Ib, open-label first-in-human study of the safety, tolerability, and feasibility of gene-edited autologous NeoTCR-T cells (NeoTCR-P1) administered to patients with locally advanced or metastatic solid tumors.

M. Cristea, B. Chmielowski, S. Ejadi, 2020 .

1049OSAFETY AND EFFICACY OF MPDL3280A (ANTI-PDL1) IN COMBINATION WITH BEVACIZUMAB (BEV) AND/OR CHEMOTHERAPY (CHEMO) IN PATIENTS (PTS) WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS.

H. Hurwitz, J. Bendell, M. Pishvaian, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The oncologist.

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer.

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The oncologist.

1478 A phase I study of personalized adoptive TCR T cell therapy in patients with solid tumors: safety, efficacy, and T cell trafficking to tumors of non-virally gene edited T cells

D. Baltimore, J. Sosman, A. Ribas, 2022, Late-Breaking Abstracts.

H. Wakelee, V. Miller, M. Pietanza, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer

P. Hegde, E. Van Cutsem, H. Hurwitz, 2017, The Oncologist.

A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors.

P. Hegde, P. Munster, L. Naumovski, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

G. Giaccone, F. Hodi, S. Gettinger, 2015 .